Arcutis Biotherapeutics Inc. (ARQT) News
Filter ARQT News Items
ARQT News Results
| Date | Symbol | Company | Title | Start | End | Change | POWR Rating | ||
|---|---|---|---|---|---|---|---|---|---|
| Loading, please wait... | |||||||||
ARQT News Highlights
- ARQT's 30 day story count now stands at 11.
- Over the past 22 days, the trend for ARQT's stories per day has been choppy and unclear. It has oscillated between 1 and 2.
- The most mentioned tickers in articles about ARQT are DERM, SEB and ARM.
Latest ARQT News From Around the Web
Below are the latest news stories about ARCUTIS BIOTHERAPEUTICS INC that investors may wish to consider to help them evaluate ARQT as an investment opportunity.
Arcutis Appoints L. Todd Edwards as Chief Commercial OfficerTodd Edwards Chief Commercial Officer, Arcutis Biotherapeutics Industry veteran with deep commercial experience in dermatology and immunologyAyisha Jeter appointed Senior Vice President, Marketing and Market Access WESTLAKE VILLAGE, Calif., Sept. 27, 2023 (GLOBE NEWSWIRE) -- Arcutis Biotherapeutics, Inc. (Nasdaq: ARQT), an early commercial-stage biopharmaceutical company focused on developing meaningful innovations in immuno-dermatology, today announced the appointment of Todd Edwards as Chief C |
Roivant Sciences Ltd. (ROIV) Moves 21.6% Higher: Will This Strength Last?Roivant Sciences Ltd. (ROIV) saw its shares surge in the last session with trading volume being higher than average. The latest trend in earnings estimate revisions may not translate into further price increase in the near term. |
Mizuho reaffirms 'Buy' recommendation for Arcutis Biotherapeutics, amidst mixed institutional sentimentOn Monday, Mizuho, a notable financial institution, maintained its 'Buy' recommendation for Arcutis Biotherapeutics (NASDAQ:ARQT), a late-stage biopharmaceutical company. This comes despite the mixed institutional sentiment towards the firm, which specializes in immune-mediated dermatological diseases and conditions. |
New Campaign from Arcutis Aims to Educate, Raise Awareness, and Provide Encouragement for Those Living with Seborrheic DermatitisWESTLAKE VILLAGE, Calif., Sept. 25, 2023 (GLOBE NEWSWIRE) -- Arcutis Biotherapeutics, Inc. (NASDAQ: ARQT), an early commercial-stage company focused on developing meaningful innovations in immuno-dermatology, today announced the launch of an educational campaign designed to elevate understanding, connection, and encouragement for those living with seborrheic dermatitis, or Seb Derm for short. The campaign, Clearing Up Seb Derm, features expert advice from leading dermatologists and personal stor |
Arcutis Announces Positive Results from INTEGUMENT-PED Pivotal Phase 3 Trial of Roflumilast Cream 0.05% for the Treatment of Atopic Dermatitis in Children Ages 2 to 5Study met the primary endpoint and all secondary endpoints, highly consistent with rapid response from the INTEGUMENT-1 and INTEGUMENT-2 pivotal trialsFor the primary endpoint, 25.4% of children treated once daily with roflumilast cream 0.05% achieved Investigator Global Assessment (IGA) Success compared to 10.7% of children treated with vehicle (P<0.0001) at Week 4, with significant improvements seen as early as Week 139.4% of children treated with roflumilast cream 0.05% achieved a 75% improve |
Arcutis Biotherapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)WESTLAKE VILLAGE, Calif., Sept. 15, 2023 (GLOBE NEWSWIRE) -- Arcutis Biotherapeutics, Inc. (Nasdaq: ARQT), an early commercial-stage biopharmaceutical company focused on developing meaningful innovations in immuno-dermatology, today reported the grant of an aggregate of 39,000 restricted stock units of Arcutis’ common stock to six newly hired employees. These awards were approved by the Compensation Committee of Arcutis’ Board of Directors and granted under the Arcutis Biotherapeutics, Inc. 2022 |
Arcutis (ARQT) Files sNDA for Zoryve in Atopic Dermatitis, Stock UpArcutis (ARQT) submits sNDA, seeking label expansion of Zoryve (roflumilast) cream 0.15% to treat patients with atopic dermatitis. |
Arcutis Submits Roflumilast Cream 0.15% Supplemental New Drug Application to the FDA for the Treatment of Atopic Dermatitis in Adults and Children Ages 6 Years and OlderAtopic dermatitis is the most common type of eczema, affecting approximately 9.6 million children and 16.5 million adults in the United StatesIn pivotal Phase 3 trials, roflumilast cream demonstrated statistically significant improvements over vehicle on the primary endpoint of Investigator Global Assessment (IGA) Success at Week 4, as well as on key secondary endpoints including rapid improvement in itchRoflumilast cream was well tolerated and demonstrated a favorable safety and tolerability pr |
Why Shares of Arcutis Biotherapeutics Fell This WeekShares of Arcutis Biotherapeutics (NASDAQ: ARQT) were down 15.7% for the week as of 2:45 p.m. on Thursday, according to data provided by S&P Global Market Intelligence. The healthcare company's stock closed last week at $8.96 a share and fell to as low as $7.47 on Thursday after Arcutis reported trial data regarding a prospective atopic dermatitis therapy. On Thursday, Arcutis reported interim results from its study of Zoryve (roflumilast) cream for patients six years and older with atopic dermatitis. |
Arcutis Announces Positive Long-Term Results of Roflumilast Cream 0.15% Showing Durable and Improved Efficacy Over Time and Favorable Safety Profile in Treatment of Mild to Moderate Atopic Dermatitis (AD)Results for adults and children ages 6 years and older from INTEGUMENT-OLE long-term extension trial highlight that 46.1% and 51.0% of patients who rolled over from the roflumilast cream treatment arm in INTEGUMENT-1 or -2 achieved IGA success at Week 28 and Week 56, respectivelyRoflumilast cream maintained disease control even when participants switched to twice weekly maintenance dosing scheduleLong-term safety and tolerability profile consistent with short-term data in AD, with no new safety |